BridgeBio Pharma Inc
For the period ended Mar 31, 2024. Filed May 2, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 2, 2024
BBIO$78.67+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenue | $211,120 | $1,826 |
| Operating costs and expenses: | ||
| Cost of revenue | 598 | 651 |
| Research and development | 140,972 | 92,861 |
| Selling, general and administrative | 65,807 | 31,108 |
| Restructuring, impairment and related charges | 3,400 | 3,369 |
| Total operating costs and expenses | 210,777 | 127,989 |
| Income (loss) from operations | 343 | (126,163) |
| Other expense, net: | ||
| Interest income | 4,075 | 4,153 |
| Interest expense | (23,471) | (20,121) |
| Loss on extinguishment of debt | (26,590) | — |
| Other income (expense), net | 9,483 | (601) |
| Total other expense, net | (36,503) | (16,569) |
| Net loss | (36,160) | (142,732) |
| Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | 944 | 2,576 |
| Net loss attributable to common stockholders of BridgeBio | $(35,216) | $(140,156) |
| Net loss per share attributable to common stockholders of BridgeBio, basic and diluted | $(0.20) | $(0.92) |
| Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic and diluted | 178,705,310 | 152,645,635 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.